Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery

Abstract

Artemisinin, the most famous anti-malaria drug initially extracted from Artemisia annua L., also exhibits anti-tumor properties in vivo and in vitro. To improve its solubility and bioavailability, multiple derivatives have been synthesized. However, to reveal the anti-tumor mechanism and improve the efficacy of these artemisinin-type drugs, studies have been conducted in recent years. In this review, we first provide an overview of the effect of artemisinin-type drugs on the regulated cell death pathways, which may uncover novel therapeutic approaches. Then, to overcome the shortcomings of artemisinin-type drugs, we summarize the recent advances in two different therapeutic approaches, namely the combination therapy with biologics influencing regulated cell death, and the use of nanocarriers as drug delivery systems. For the former approach, we discuss the superiority of combination treatments compared to monotherapy in tumor cells based on their effects on regulated cell death. For the latter approach, we give a systematic overview of nanocarrier design principles used to deliver artemisinin-type drugs, including inorganic-based nanoparticles, liposomes, micelles, polymer-based nanoparticles, carbon-based nanoparticles, nanostructured lipid carriers and niosomes. Both approaches have yielded promising findings in vitro and in vivo, providing a strong scientific basis for further study and upcoming clinical trials.

Unrevealing the therapeutic potential of artesunate against emerging zoonotic Babesia microti infection in the murine model

“…Beyond its direct antiparasitic properties, AS may have additional therapeutic benefits due to its capacity to regulate the expression of apoptotic proteins Bax, Beclin, and Caspase activity through the destruction of contaminated cells, stop the infection from spreading, and encourage tissue regeneration ( 40 ). Recently, documented studies on 56 phytochemicals including AS showed significant reduction in TNF-α, IL2, CD44, and IFN-γ via NF-kB pathways in vitro and in vivo models ( 41 ).…”

Nanotechnology-based delivery systems to overcome drug resistance in cancer

“…In vitro and in vivo studies have reported that ART has antitumor, antifungal, anti-malarial, and anti-ulcer efficacy [ 204 ]. However, ART has a lower solubility in water, a shorter half-life and an increased first-passage metabolism, which limits its therapeutic efficacy [ 205 ]. The synthesis of ART-containing NPs improve the pharmacokinetic profile of ART and increase the in vivo efficacy of ART.…”

Advances in Nanodynamic Therapy for Cancer Treatment

“…Over the past few years, extensive research has been undertaken by many scholars on nanodynamic therapies aimed at combating tumors. This study spans the spectrum of innovative nanocarriers to optimize the TME and integrate various therapeutic strategies [26]. These efforts are based on catalyzing the production of reactive ROS within tumor cells and inducing tumor cell death.…”